- Home
- FFA vs PACB Comparison
FFA vs PACB Comparison
Compare FFA & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFA
- PACB
- Stock Information
- Founded
- FFA 2004
- PACB 2000
- Country
- FFA United States
- PACB United States
- Employees
- FFA N/A
- PACB N/A
- Industry
- FFA Investment Managers
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- FFA Finance
- PACB Industrials
- Exchange
- FFA Nasdaq
- PACB Nasdaq
- Market Cap
- FFA 416.1M
- PACB 381.5M
- IPO Year
- FFA N/A
- PACB 2010
- Fundamental
- Price
- FFA $21.46
- PACB $1.17
- Analyst Decision
- FFA
- PACB Buy
- Analyst Count
- FFA 0
- PACB 7
- Target Price
- FFA N/A
- PACB $1.90
- AVG Volume (30 Days)
- FFA 26.1K
- PACB 4.9M
- Earning Date
- FFA 01-01-0001
- PACB 11-06-2025
- Dividend Yield
- FFA 6.72%
- PACB N/A
- EPS Growth
- FFA N/A
- PACB N/A
- EPS
- FFA N/A
- PACB N/A
- Revenue
- FFA N/A
- PACB $156,110,000.00
- Revenue This Year
- FFA N/A
- PACB $5.26
- Revenue Next Year
- FFA N/A
- PACB $16.13
- P/E Ratio
- FFA N/A
- PACB N/A
- Revenue Growth
- FFA N/A
- PACB N/A
- 52 Week Low
- FFA $15.84
- PACB $0.85
- 52 Week High
- FFA $19.30
- PACB $2.72
- Technical
- Relative Strength Index (RSI)
- FFA 65.77
- PACB 40.05
- Support Level
- FFA $21.25
- PACB $1.21
- Resistance Level
- FFA $21.52
- PACB $1.32
- Average True Range (ATR)
- FFA 0.16
- PACB 0.06
- MACD
- FFA 0.01
- PACB -0.01
- Stochastic Oscillator
- FFA 89.09
- PACB 4.55
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.